Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advise
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc (GSK)
01:00pm, Thursday, 27'th Mar 2025
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.
Levi & Korsinsky Reminds GSK plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
12:30pm, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
GSK plc Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - GSK
12:00pm, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
Shareholders that Lost Money on GSK plc (GSK) Should Contact Levi & Korsinsky About Pending Class Action - GSK
10:30am, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
07:25am, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK p
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK plc Lawsuit - GSK
05:45am, Thursday, 27'th Mar 2025
NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc(GSK) Shareholders
07:15pm, Wednesday, 26'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
09:01am, Wednesday, 26'th Mar 2025
The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are adv
Investors in GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
07:25am, Wednesday, 26'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
NEW YORK CITY, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK p
4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a potential best
